Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration for Clindamycin Phosphate Foam, 1%, a generic version of EVOCLIN® Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12 month period ending April 2019, the EVOCLIN® Foam, 1% market achieved annual sales of approximately $17.0 million.

Glenmark’s current portfolio consists of 156 products authorized for distribution in the U.S. marketplace and 59 ANDA’s pending approval with the USFDA.